Bladder Cancer (Amsterdam, Netherlands)最新文献

筛选
英文 中文
The July Effect in Radical Cystectomy: Mortality, Morbidity, and Efficiency 根治性膀胱切除术的七月效应:死亡率、发病率和效率
Bladder Cancer (Amsterdam, Netherlands) Pub Date : 2016-10-24 DOI: 10.3233/BLC-160059
K. Zuk, Derek Jensen, J. Gills, Hadley W. Wyre, J. Holzbeierlein, Ernesto López-Corona, Eugene K Lee
{"title":"The July Effect in Radical Cystectomy: Mortality, Morbidity, and Efficiency","authors":"K. Zuk, Derek Jensen, J. Gills, Hadley W. Wyre, J. Holzbeierlein, Ernesto López-Corona, Eugene K Lee","doi":"10.3233/BLC-160059","DOIUrl":"https://doi.org/10.3233/BLC-160059","url":null,"abstract":"Background: The “July effect” is the potential effect that new and recently promoted residents have on patient care during the first months of the academic year. Literature suggests that the July effect may worsen patient outcomes and lead to systemic inefficiencies. Objective: We evaluate the July effect on mortality, morbidity, and efficiency outcomes in patients undergoing radical cystectomy. Methods: A chart review was performed in patients who underwent radical cystectomy between January 2008 and April 2012. Demographic information was abstracted from patient charts and outcomes compared between operations performed in July, September, and November (first month of each resident’s university rotation) to the remainder of the year. Outcomes of interest included mortality, complications, and markers of efficiency (operative time, length of hospital stay, and estimated blood loss). Results: Two hundred and fifty one patients were included in the analysis. There were no major differences in mortality or morbidity between the July, September, November group and the rest of the year. Multivariable analysis demonstrates a trend for operations performed in the months of July, September, and November to be associated with longer OR times 2.06 (0.99–4.27), p = 0.053. Length of hospital stay and estimated blood loss were no different between the two groups. Conclusions: These data demonstrate no increase in mortality or morbidity during the early academic period. Additionally, while there is a trend for OR time to be longer in the early group, length of hospital stay and estimated blood loss were no different. These data may be used as an impetus to continue to investigate technical/clinical teaching practices, strategies to assess resident progression, and to initiate protocols to support residents early in the academic year in efforts to prevent inefficiencies.","PeriodicalId":290379,"journal":{"name":"Bladder Cancer (Amsterdam, Netherlands)","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123555436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer 经尿道切除在肌侵性膀胱癌三段式治疗中的作用
Bladder Cancer (Amsterdam, Netherlands) Pub Date : 2016-10-24 DOI: 10.3233/BLC-160076
C. Russell, A. Lebastchi, T. Borza, D. Spratt, T. Morgan
{"title":"The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer","authors":"C. Russell, A. Lebastchi, T. Borza, D. Spratt, T. Morgan","doi":"10.3233/BLC-160076","DOIUrl":"https://doi.org/10.3233/BLC-160076","url":null,"abstract":"While radical cystectomy (RC) with pelvic lymph node dissection (PLND) represents the accepted gold standard for the treatment of muscle-invasive bladder cancer, this treatment approach is associated with significant morbidity. As such, bladder preservation strategies are often utilized in patients who are either deemed medically unfit due to significant comorbidities or whom decline management with RC and PLND secondary to its associated morbidity. In a select group of patients, meeting strict criteria, bladder preservation approaches may be employed with curative intent. Trimodal therapy, consisting of complete transurethral resection of bladder tumor (TURBT), chemotherapy, and radiation therapy has demonstrated durable oncologic control and long-term survival in a number of studies. The review presented here provides a description of trimodal therapy and the role of TURBT in bladder preservation for patients with muscle-invasive bladder cancer.","PeriodicalId":290379,"journal":{"name":"Bladder Cancer (Amsterdam, Netherlands)","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132168952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact? 新辅助化疗对根治性膀胱切除术后肾功能的影响:是否有意义?
Bladder Cancer (Amsterdam, Netherlands) Pub Date : 2016-10-24 DOI: 10.3233/BLC-160071
T. Chandrasekar, Neil Pugashetti, B. Durbin-Johnson, M. Dall’Era, C. Evans, R. deVere White, S. Yap
{"title":"Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact?","authors":"T. Chandrasekar, Neil Pugashetti, B. Durbin-Johnson, M. Dall’Era, C. Evans, R. deVere White, S. Yap","doi":"10.3233/BLC-160071","DOIUrl":"https://doi.org/10.3233/BLC-160071","url":null,"abstract":"Objective: To evaluate the patterns of impact of neoadjuvant chemotherapy (NAC) on renal function across the initial year following treatment for muscle-invasive bladder cancer (MIBC) with radical cystectomy (RC). Methods: We reviewed the charts of 241 patients who underwent RC for urothelial carcinoma of the bladder between 2003-14 at our institution. Renal function was evaluated at multiple time points (pre-chemotherapy, pre-operatively, post-operatively, 6–12 months follow-up), and then classified by CKD staging. Univariable and multivariable logistic regression analyses were performed to determine relationship between NAC and change in CKD stage. Results: Of the 241 patients who underwent RC for urothelial carcinoma of the bladder, 66 (27%) received NAC and 175 (73%) did not. In multivariable analysis, NAC was significantly associated with a decrease of at least one CKD stage from baseline to post-op (p = 0.009), but not to the 6–12 months follow-up time point (p = 0.050). The loss of GFR in the NAC cohort occurs up-front with chemotherapy, but the peri-operative course is similar to those who underwent cystectomy alone. Of the 15 NAC patients (26.8%) who were Stage 3 CKD prior to chemotherapy, none progressed to a higher stage CKD. Conclusion: NAC is associated with an initial decline in GFR, which then remains stable through the first year following RC. Despite an initial insult, patients receiving NAC are not vulnerable to further deterioration. When appropriately selected, NAC does not appear to result in a clinically significant deterioration of renal function.","PeriodicalId":290379,"journal":{"name":"Bladder Cancer (Amsterdam, Netherlands)","volume":"69 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128679492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Checkpoint Inhibitors for Advanced Bladder Cancer 晚期膀胱癌的检查点抑制剂
Bladder Cancer (Amsterdam, Netherlands) Pub Date : 2016-10-24 DOI: 10.3233/BLC-169011
E. Messing
{"title":"Checkpoint Inhibitors for Advanced Bladder Cancer","authors":"E. Messing","doi":"10.3233/BLC-169011","DOIUrl":"https://doi.org/10.3233/BLC-169011","url":null,"abstract":"Metastatic urothelial cancer (UC) recurring after cisplatin based combination chemotherapy represents an incurable condition for which treatment with second line chemotherapy is almost always unsuccessful in achieving prolonged remissions. The recent introduction into the therapeutic armamentarium of immune checkpoint inhibitors can potentially be a “game changer”, although success currently remains limited. UC is one of the cancers with many somatic mutations, along with melanoma and non-small cell lung cancer (NSCLC) [1] and there are data associating mutational burden with response to checkpoint inhibitors in NSCLC [2] and melanoma [3]. Initially for UC this approach focused on cytotoxic T lymphocyte-associated protein 4 (CTLA4) inhibitors, which blocked the immune system’s recognition of tumor-induced molecular signals which diminish immune responses to cancers. The CTLA-4 inhibitor, ipilimumab, caused more immune T lymphocytes to infiltrate UCs, but did not result, alone or combined with Gemcitabine– cisplatin therapy, in prolonging survival [4]. However, attacking another immune checkpoint, programmed death receptor and programmed death receptor ligand 1 (PD-1 and PD-L1, respectively) has effected prolonged survival in some UC patients. We will review recent studies using this approach, which holds great promise. Powles, et al., [5] examined activity of the high affinity human anti-PD-L1 antibody, MPDL3280A (atezolizumab), in patients with metastatic UC in","PeriodicalId":290379,"journal":{"name":"Bladder Cancer (Amsterdam, Netherlands)","volume":"894 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117048499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma PD-L1表达和瘤内淋巴细胞在尿路上皮癌围手术期化疗中的作用
Bladder Cancer (Amsterdam, Netherlands) Pub Date : 2016-10-24 DOI: 10.3233/BLC-160067
F. Erlmeier, A. Seitz, G. Hatzichristodoulou, L. Stecher, M. Retz, J. Gschwend, W. Weichert, H. Kübler, T. Horn
{"title":"The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma","authors":"F. Erlmeier, A. Seitz, G. Hatzichristodoulou, L. Stecher, M. Retz, J. Gschwend, W. Weichert, H. Kübler, T. Horn","doi":"10.3233/BLC-160067","DOIUrl":"https://doi.org/10.3233/BLC-160067","url":null,"abstract":"Introduction: Immunological pathways are relevant for the effectiveness of conventional cytotoxic chemotherapy. Recently, checkpoint inhibition of the PD-1/PD-L1 axis has been shown to be therapeutically relevant in urothelial carcinoma. Objective: To monitor PD-L1 expression on tumor cells and intratumoral infiltration with CD8 positive lymphocytes during perioperative chemotherapy for urothelial cancer and to evaluate their use as potential predictive markers for chemotherapy. Patients and Methods: Sixty-four patients with muscle-invasive urothelial cancer were included in the analysis. Twenty-two patients received preoperative chemotherapy and 42 were treated in an adjuvant setting for locally advanced disease or lymph node metastases. PD-L1 status and the density of infiltration with CD8-positive cells were assessed by immunohistochemistry and analysed for their association with survival (adjuvant group) and response to chemotherapy (preoperative group). For PD-L1 positivity we used a cutoff of 10% positive tumor cells. Results: In the adjuvant group, 11 of 42 patients (26.2%) had PD-L1 positive tumor cells. Twenty-six of 42 (61.9%) patients were highly infiltrated with CD8 + lymphocytes. There was no significant evidence of an association with overall survival for PD-L1 status nor for CD8 infiltration density (p = 0.63 and 0.71). In the preoperative group, eight of the 22 (36.4%) patients were PD-L1 positive and 13 (59%) were highly infiltrated with CD8 + lymphocytes before chemotherapy. There was no evidence of associations with response or survival. Eight patients showed a pathological response to preoperative treatment. These had a significantly longer overall survival than non-responders (p = 0.01). In the preoperative group the pre-treatment expression of the immunologic markers could be compared to the post-treatment status. Only one patient showed a changed PD-L1 status and three patients a changed CD8 status. Conclusions: The tumoral expression of PD-L1 in urothelial carcinoma does not seem to be largely influenced by chemotherapy. Our data do not provide evidence that tumoral expression of PD-L1 and CD8 are useful as prognostic or predictive markers. Small sample size is the major limitation of our study.","PeriodicalId":290379,"journal":{"name":"Bladder Cancer (Amsterdam, Netherlands)","volume":"69 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115716119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 23
Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer 肌肉浸润性膀胱癌膀胱保留治疗的应用模式
Bladder Cancer (Amsterdam, Netherlands) Pub Date : 2016-10-24 DOI: 10.3233/BLC-160072
T. Rose, A. Deal, S. Ladoire, G. Créhange, M. Galsky, J. Rosenberg, J. Bellmunt, A. Wimalasingham, Y. Wong, L. Harshman, S. Chowdhury, G. Niegisch, M. Liontos, E. Yu, S. Pal, Ronald C. Chen, Andrew Z. Wang, M. Nielsen, Angela B Smith, M. Milowsky
{"title":"Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer","authors":"T. Rose, A. Deal, S. Ladoire, G. Créhange, M. Galsky, J. Rosenberg, J. Bellmunt, A. Wimalasingham, Y. Wong, L. Harshman, S. Chowdhury, G. Niegisch, M. Liontos, E. Yu, S. Pal, Ronald C. Chen, Andrew Z. Wang, M. Nielsen, Angela B Smith, M. Milowsky","doi":"10.3233/BLC-160072","DOIUrl":"https://doi.org/10.3233/BLC-160072","url":null,"abstract":"Background: Trimodality bladder preservation therapy (BPT) in muscle invasive bladder cancer (MIBC) includes a maximal transurethral resection followed by concurrent chemoradiotherapy as an alternative to radical cystectomy (RC) in appropriately selected patients, or as a treatment option in non-cystectomy candidates. Several chemotherapy regimens can be used in BPT, but little is known about current practice patterns. Objective: To describe utilization patterns of BPT and associated survival outcomes in MIBC. Methods: Data were collected from the Retrospective International Study of Cancers of the Urothelial Tract (RISC), a database of 3,024 consecutive patients from 29 international academic centers from 2005 to 2013. Patients with clinical T2-T4aN0M0 urothelial cancer of the bladder were included. Results: 265 patients received BPT. Compared with the 1,447 patients who received RC, BPT patients were older, had poorer performance status, and had more comorbidities (p < 0.01 for all). Median overall survival (OS) was similar for patients treated with curative radiation doses in BPT and patients treated with RC (41 vs 46 months, p = 0.33, respectively). 45% of BPT patients received concurrent chemotherapy with radiation. The most common regimens included cisplatin alone (23%), carboplatin alone (22%), gemcitabine alone (10%), paclitaxel alone (9%), and 5-FU+mitomycin (5%). There were no significant differences in survival among chemotherapy regimens. Only 10 patients (4% of BPT patients) underwent salvage cystectomy. Conclusions: In clinical practice, BPT patients have similar survival to RC patients when treated with curative radiotherapy doses. Choice of concurrent chemotherapy regimen varied widely with no clear standard. Salvage cystectomy is rarely performed. Continued research is needed on the comparative effectiveness among BPT and RC, and among chemotherapy regimens in BPT.","PeriodicalId":290379,"journal":{"name":"Bladder Cancer (Amsterdam, Netherlands)","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122386603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Bladder Cancer Screening in Lebanese Population: There is Nothing more Unequal than the Equal Treatment of Unequal People 黎巴嫩人口膀胱癌筛查:没有什么比不平等人群的平等待遇更不平等了
Bladder Cancer (Amsterdam, Netherlands) Pub Date : 2016-10-12 DOI: 10.3233/BLC-160074
M. Shahait, M. Bulbul
{"title":"Bladder Cancer Screening in Lebanese Population: There is Nothing more Unequal than the Equal Treatment of Unequal People","authors":"M. Shahait, M. Bulbul","doi":"10.3233/BLC-160074","DOIUrl":"https://doi.org/10.3233/BLC-160074","url":null,"abstract":"Bladder cancer screening has been perplexing the uro-oncological community for the last decade. In this commentary, we ruminate on the feasibility of bladder cancer screening in our population based on epidemiological proponents.","PeriodicalId":290379,"journal":{"name":"Bladder Cancer (Amsterdam, Netherlands)","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126669842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG 膀胱内卡介苗治疗后膀胱癌疾病状态的澄清
Bladder Cancer (Amsterdam, Netherlands) Pub Date : 2015-03-30 DOI: 10.3233/BLC-159002
S. Lerner, C. Dinney, A. Kamat, T. Bivalacqua, M. Nielsen, M. O'Donnell, M. Schoenberg, G. Steinberg
{"title":"Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG","authors":"S. Lerner, C. Dinney, A. Kamat, T. Bivalacqua, M. Nielsen, M. O'Donnell, M. Schoenberg, G. Steinberg","doi":"10.3233/BLC-159002","DOIUrl":"https://doi.org/10.3233/BLC-159002","url":null,"abstract":"At the most recent Genitourinary Cancers Symposium in Orlando February 2015, a task force was organized to discuss issues in trial design in non-muscle invasive bladder cancer. Our aim was to provide further clarification regarding disease states following treatment of patients with intravesical BCG and to determine what events constitute progression following any treatment for non-muscle invasive bladder cancer (NMIBC). The panelists were asked to address a number of specific Tasks, enumerated below.","PeriodicalId":290379,"journal":{"name":"Bladder Cancer (Amsterdam, Netherlands)","volume":"47 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116098464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 84
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书